| 主权项 |
1. A method for treating CLL or T-PLL, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having CLL or T-PLL, wherein the Dihydropyrazino-Pyrazine Compound is a compound of formula (I): and pharmaceutically acceptable salts, clathrates, solvates, stereoisomers, tautomers, metabolites, isotopologues and prodrugs thereof, wherein: R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R2 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R3 is H, or a substituted or unsubstituted C1-8 alkyl, provided the Dihydropyrazino-Pyrazine Compound is not 7-(4-hydroxyphenyl)-1-(3-methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. |
